An Open-Label, Parallel-Group, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delayed-Release Dimethyl Fumarate in Chinese, Japanese, and Caucasian Adult Healthy Volunteers.

被引：0
|
作者：
Tibung, J. T. [1 ]
Nestorov, I. [2 ]
McNeill, M. [3 ]
Li, J. [2 ]
Zhu, B. [2 ]
机构：
[1] Biogen Ltd, Tokyo, Japan
[2] Biogen Inc, 14 Cambridge Ctr, Cambridge, MA 02142 USA
[3] Biogen UK Ltd, Maidenhead, Berks, England
来源：
MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P-47
引用
收藏
页码：422 / 422
页数：1
相关论文
共 50 条
  • [21] The Pharmacokinetics, Safety, and Tolerability of Rimegepant 75 mg are Similar in Elderly and Nonelderly Adults: a Phase 1, Open-Label, Parallel-Group, Single-Dose Study
    Croop, R.
    Stringfellow, J.
    Ivans, A.
    Coric, V
    HEADACHE, 2019, 59 : 177 - 178
  • [22] The Pharmacokinetics, Safety, and Tolerability of Rimegepant 75 mg Are Similar in Elderly and Nonelderly Adults: A Phase 1, Open-Label, Parallel-Group, Single-Dose Study
    Bhardwaj, Rajinder
    Morris, Beth
    Bertz, Richard
    Croop, Robert
    Liu, Jing
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (01): : 37 - 44
  • [23] Pharmacokinetics and Safety of Single and Multiple Doses of Oral N-Acetylcysteine in Healthy Chinese and Caucasian Volunteers: An Open-Label, Phase I Clinical Study
    Alberto Papi
    Andrea F. D. Di Stefano
    Milko Radicioni
    Advances in Therapy, 2021, 38 : 468 - 478
  • [24] Pharmacokinetics and Safety of Single and Multiple Doses of Oral N-Acetylcysteine in Healthy Chinese and Caucasian Volunteers: An Open-Label, Phase I Clinical Study
    Papi, Alberto
    Di Stefano, Andrea F. D.
    Radicioni, Milko
    ADVANCES IN THERAPY, 2021, 38 (01) : 468 - 478
  • [25] Phase 1 open-label study evaluating pharmacokinetics, safety, and tolerability of linifanib in Japanese patients with solid tumors
    Tamura, Tomohide
    Yamamoto, Noboru
    Nokihara, Hiroshi
    Yamada, Yasuhide
    Asahina, Hajime
    Shibata, Takashi
    Goto, Yasushi
    Tanioka, Maki
    Tamura, Yosuke
    Seki, Yoshitaka
    Chiu, Yi-Lin
    Gupta, Neeraj
    Carlson, Dawn
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [26] Phase 1 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Garadacimab (CSL312) in Healthy Japanese and Caucasian Adults
    Glassman, Fiona
    Goodson, Summer
    Bica, Alex
    Roberts, Anthony
    Akama, Hideto
    Asami, Yumiko
    Jain, Meena
    Acharya, Milin
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB144 - AB144
  • [27] Pharmacokinetics and safety evaluation of oral Palonosetron in Chinese healthy volunteers: A phase 1, open-label, randomized, cross-over study
    Chen, Rui
    Wang, Hongyun
    Zhong, Wen
    Chessari, Salvatore
    Lanzarotti, Corinna
    Bernareggi, Alberto
    Hu, Pei
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 160
  • [28] An Open-Label, Single-Dose, Parallel-Group, Dose-Increasing Study Comparing the Pharmacokinetics and Tolerability of Pilsicainide Hydrochloride in Healthy Korean and Japanese Male Subjects
    Kim, Bo-Hyung
    Kim, Jung-Ryul
    Lim, Kyoung Soo
    Kim, Jae Woo
    Kim, Kyu-pyo
    Hong, Jang-Hee
    Jang, In-Jin
    Shin, Sang-Goo
    Yu, Kyung-Sang
    Tanaka, Takanori
    CLINICAL THERAPEUTICS, 2009, 31 (03) : 609 - 618
  • [29] Tolerability and Pharmacokinetics of Ranolazine Following Single and Multiple Sustained-release Doses in Chinese Healthy Adult Volunteers A Randomized, Open-label, Latin Square Design, Phase I Study
    Tan, Qin-You
    Li, Huan-De
    Zhu, Rong-Hua
    Zhang, Qi-Zhi
    Zhang, Jun
    Peng, Wen-Xing
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2013, 13 (01) : 17 - 25
  • [30] Pharmacokinetics of capmatinib in participants with hepatic impairment: A phase 1, open-label, single-dose, parallel-group study
    Chen, Xinhui
    Cui, Xiaoming
    Pognan, Nathalie
    Quinlan, Michelle
    Kapoor, Shruti
    Rahmanzadeh, Gholamreza
    Giovannini, Monica
    Marbury, Thomas C.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (01) : 91 - 102
12345